Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%

Berotralstat vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.77 [0.02, 24.03]
3 studies · 128 participants
Low

C1 esterase inhibitor vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.34 [0.01, 8.14]
1 study · 44 participants
Very low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.54 [0.09, 3.1]
1 study · 71 participants
Very low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.5 [0.06, 34.66]
1 study · 29 participants
Very low

Avoralstat vs placebo

Serious adverse events (during · children or adults with Types I or II HAE

It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.8]
1 study · 24 participants
Very low

Lanadelumab vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.88 [0.08, 10.39]
2 studies · 162 participants
Low